Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.35 |
| ▸ | RAB9A | P51151 | 6/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163659 | 0.87 | APP (0.39) | APPRAD51NPC1RAB9ATOP2A | |
| SCHEMBL484285 | 0.85 | RAD51 (0.40) | APPRAD51NPC1RAB9AADORA2A | |
| SCHEMBL2163112 | 0.85 | APP (0.37) | APPRAD51TOP2A | |
| SCHEMBL2162661 | 0.85 | APP (0.37) | APPRAD51TOP2AMAPTPKM | |
| SCHEMBL12402982 | 0.84 | APP (0.41) | APPNPC1RAB9AMAPTHRH3 | |
| SCHEMBL12323589 | 0.82 | ALDH1A1 (0.40) | APPRAD51NPC1RAB9AMAPT | |
| SCHEMBL2163599 | 0.82 | APP (0.39) | APPMAPTTP53ALDH1A1MEN1 | |
| SCHEMBL12323637 | 0.82 | TOP2A (0.37) | APPRAD51NPC1RAB9ATOP2A | |
| SCHEMBL12403622 | 0.81 | TP53 (0.40) | APPNPC1RAB9AADORA2AMAPT | |
| SCHEMBL12402841 | 0.81 | RAD51 (0.40) | RAD51NPC1RAB9AADORA2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411057-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2411057-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-8491869-B2 | Imaging agents for detecting neurological disorders | ELI LILLY AND COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| US-8491869-B2 | Imaging agents for detecting neurological disorders | ELI LILLY AND COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2411057-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | Siemens Medical Solutions USA, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011119565-A1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010111303-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111303-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | APP 2/4885RAD51 1648/4885NPC1 68/4885 |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | APP 2/4885RAD51 1902/4885NPC1 143/4885 |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | MAPT, APP, PSEN1 | APP 2/4885RAD51 1648/4885NPC1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.